Abstract
Routine use of the pneumococcal conjugate vaccines (PCV7 and PCV13), beginning in 2000, has resulted in a dramatic reduction in the incidence of invasive pneumococcal disease (IPD) attributable to serotypes of Streptococcus pneumoniae contained in the vaccines. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the American Academy of Pediatrics recommend the expanded use of PCV13 in children 6 through 18 years of age with certain conditions that place them at elevated risk of IPD. This statement provides recommendations for the use of PCV13 in children 6 through 18 years. A single dose of PCV13 should be administered to certain children in this age group who are at elevated risk of IPD. Recommendations for the use of PCV13 in healthy children and for pneumococcal polysaccharide vaccine (PPSV23) remain unchanged.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1230-1233 |
| Number of pages | 4 |
| Journal | Pediatrics |
| Volume | 134 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 1 2014 |
Fingerprint
Keywords
- Immunization
- Invasive pneumococcal disease
- PCV13
- PPSV23
- Pneumococcal vaccine
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
Immunization for Streptococcus pneumoniae infections in high-risk children. / Byington, Carrie L.; Maldonado, Yvonne A.; Barnett, Elizabeth D.; Davies, Herbert Dele; Edwards, Kathryn M.; Jackson, Mary Anne; Murray, Dennis L.; Rathore, Mobeen H.; Sawyer, Mark H.; Schutze, Gordon E.; Willoughby, Rodney E.; Zaoutis, Theoklis E.; Frantz, Jennifer M.; Campos-Outcalt, Doug; Fischer, Marc A.; Gellin, Bruce G.; Gorman, Richard L.; Lee, Lucia H.; Pratt, R. Douglas; Robinson, Joan L.; Safadi, Marco Aurelio Palazzi; Seward, Jane F.; Starke, Jeffrey R.; Simon, Geoffrey R.; Tan, Tina Q.
In: Pediatrics, Vol. 134, No. 6, 01.12.2014, p. 1230-1233.Research output: Contribution to journal › Short survey
}
TY - JOUR
T1 - Immunization for Streptococcus pneumoniae infections in high-risk children
AU - Byington, Carrie L.
AU - Maldonado, Yvonne A.
AU - Barnett, Elizabeth D.
AU - Davies, Herbert Dele
AU - Edwards, Kathryn M.
AU - Jackson, Mary Anne
AU - Murray, Dennis L.
AU - Rathore, Mobeen H.
AU - Sawyer, Mark H.
AU - Schutze, Gordon E.
AU - Willoughby, Rodney E.
AU - Zaoutis, Theoklis E.
AU - Frantz, Jennifer M.
AU - Campos-Outcalt, Doug
AU - Fischer, Marc A.
AU - Gellin, Bruce G.
AU - Gorman, Richard L.
AU - Lee, Lucia H.
AU - Pratt, R. Douglas
AU - Robinson, Joan L.
AU - Safadi, Marco Aurelio Palazzi
AU - Seward, Jane F.
AU - Starke, Jeffrey R.
AU - Simon, Geoffrey R.
AU - Tan, Tina Q.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Routine use of the pneumococcal conjugate vaccines (PCV7 and PCV13), beginning in 2000, has resulted in a dramatic reduction in the incidence of invasive pneumococcal disease (IPD) attributable to serotypes of Streptococcus pneumoniae contained in the vaccines. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the American Academy of Pediatrics recommend the expanded use of PCV13 in children 6 through 18 years of age with certain conditions that place them at elevated risk of IPD. This statement provides recommendations for the use of PCV13 in children 6 through 18 years. A single dose of PCV13 should be administered to certain children in this age group who are at elevated risk of IPD. Recommendations for the use of PCV13 in healthy children and for pneumococcal polysaccharide vaccine (PPSV23) remain unchanged.
AB - Routine use of the pneumococcal conjugate vaccines (PCV7 and PCV13), beginning in 2000, has resulted in a dramatic reduction in the incidence of invasive pneumococcal disease (IPD) attributable to serotypes of Streptococcus pneumoniae contained in the vaccines. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the American Academy of Pediatrics recommend the expanded use of PCV13 in children 6 through 18 years of age with certain conditions that place them at elevated risk of IPD. This statement provides recommendations for the use of PCV13 in children 6 through 18 years. A single dose of PCV13 should be administered to certain children in this age group who are at elevated risk of IPD. Recommendations for the use of PCV13 in healthy children and for pneumococcal polysaccharide vaccine (PPSV23) remain unchanged.
KW - Immunization
KW - Invasive pneumococcal disease
KW - PCV13
KW - PPSV23
KW - Pneumococcal vaccine
UR - http://www.scopus.com/inward/record.url?scp=84913537300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84913537300&partnerID=8YFLogxK
U2 - 10.1542/peds.2014-2811
DO - 10.1542/peds.2014-2811
M3 - Short survey
C2 - 25422018
AN - SCOPUS:84913537300
VL - 134
SP - 1230
EP - 1233
JO - Pediatrics
JF - Pediatrics
SN - 0031-4005
IS - 6
ER -